NCT02733614View on ClinicalTrials.gov

Proof-of-concept Study to Assess the Efficacy and Safety of SRX246 in Adults With PTSD

PHASE2TerminatedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

December 31, 2016

Primary Completion Date

October 31, 2020

Study Completion Date

March 31, 2021

Conditions
PTSD
Interventions
DRUG

SRX246

novel V1a receptor antagonist

DRUG

Placebo

matching placebo

Trial Locations (1)

10065

Weill Cornell Medical College, New York

Sponsors
All Listed Sponsors
collaborator

Weill Medical College of Cornell University

OTHER

collaborator

United States Department of Defense

FED

collaborator

U.S. Army Medical Research and Development Command

FED

lead

Azevan Pharmaceuticals

INDUSTRY

NCT02733614 - Proof-of-concept Study to Assess the Efficacy and Safety of SRX246 in Adults With PTSD | Biotech Hunter | Biotech Hunter